UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Preferred Stock	Common Stock	Common Stock Payable	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Sub Total	Noncontrolling Interest	Redeemable Non-controlling Interest	Total
Balance at Jul. 31, 2018	$ 4	$ 31,402	$ 2,168,951	$ 368,379,293	$ (409,386,468)	$ 798,422	$ (38,008,396)	$ (5,576,272)		$ (43,584,668)
Balance (in shares) at Jul. 31, 2018	79,590	31,402,169
Investment in subsidiary by noncontrolling interest								228,789		228,789
Conversion of preferred series H	$ (3)	$ 28,829		(28,826)
Conversion of preferred series H (in shares)	(63,000)	28,828,953
Conversion of preferred series I	$ (1)	$ 7,584		(7,583)
Conversion of preferred series I (in shares)	(16,590)	7,583,560
Elimination of non-controlling interest				(6,951,015)			(6,951,015)			(6,951,015)
Issuance of common stock payable		8,495	(1,967,657)	1,959,162
Issuance of stock options				1,530,312			1,530,312			1,530,312
Extinguishment of debt		46		14,056,067			14,056,113			14,056,113
Issuance of warrants				9,032,435			9,032,435			9,032,435
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Conversion of debt to equity - Veneto				13,929,129			13,929,129			13,929,129
Conversion of debt to equity - Veneto (in shares)
Acquisition of NCI of Regentys								9,870,762		9,870,762
Acquisition of NCI of Olaregen								11,999,559		11,999,559
Acquisition of NCI of HDS								5,565,285		5,565,285
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Redeemable non-controlling interest									4,073,898	4,073,898
Currency translation adjustment						9,342	9,342			9,342
Settlement of subsidiary's liability with stock										0
Net Income (Loss)					(4,555,490)		(4,555,490)	(1,199,822)		(5,755,312)
Balance at Apr. 30, 2019		$ 76,356		400,828,518	(413,941,958)	807,764	(12,229,320)	21,958,757	4,073,898	13,803,335
Balance (in shares) at Apr. 30, 2019		76,356,640
Balance at Jan. 31, 2019		$ 76,356	201,294	387,364,374	(403,628,069)	800,446	(15,185,599)	21,683,698	4,073,898	10,571,997
Balance (in shares) at Jan. 31, 2019		76,356,640
Investment in subsidiary by noncontrolling interest								44,022		44,022
Issuance of stock options				605,471			605,471			605,471
Extinguishment of debt				13,929,129			13,929,129			13,929,129
Antigen dividend				(1,070,456)			(1,070,456)	1,070,456
Reclassification of equity to liability			(201,294)				(201,294)			(201,294)
Currency translation adjustment						7,318	7,318			7,318
Net Income (Loss)					(10,313,889)		(10,313,889)	(839,419)		(11,153,308)
Balance at Apr. 30, 2019		$ 76,356		400,828,518	(413,941,958)	807,764	(12,229,320)	21,958,757	$ 4,073,898	13,803,335
Balance (in shares) at Apr. 30, 2019		76,356,640
Balance at Jul. 31, 2019		$ 78,608		408,550,211	(418,727,875)	797,216	(9,301,840)	16,974,439		7,672,599
Balance (in shares) at Jul. 31, 2019		78,608,419
Stock compensation expense				1,630,111			1,630,111			1,630,111
Shares issued for services		$ 670		292,930			293,600			293,600
Shares issued for services (in shares)		669,803
Shares issued for deferred offering		$ 1,720	(767,690)	765,970
Shares issued for deferred offering (in shares)		1,719,901
Issuance of common stock for acquisitions		$ 960		1,150,992			1,151,952			1,151,952
Issuance of common stock for acquisitions (in shares)		960,000
Reduction of derivative liabilities				3,041,502			3,041,502			3,041,502
Cancellation of shares		$ (20,376)		20,376
Cancellation of shares (in shares)		(20,375,900)
Purchase of shares in subsidiary		$ 7,856		6,571,811			6,579,667	(6,579,667)
Purchase of shares in subsidiary (in shares)		7,855,912
Shares issued as debt issuance cost		$ 343		150,887			151,230			151,230
Shares issued as debt issuance cost (in shares)		343,000
Issuance of common stock payable		$ 436		935,959			936,395			936,395
Issuance of common stock payable (in shares)		436,121
Conversion of debt to equity		$ 9,720		4,480,190			4,489,910			4,489,910
Conversion of debt to equity (in shares)		9,719,740
Currency translation adjustment						(4,983)	(4,983)			(4,983)
Settlement of subsidiary's liability with stock				32,212			32,212			32,212
Net Income (Loss)					(21,661,910)		(21,661,910)	(691,484)		(22,353,394)
Balance at Apr. 30, 2020		$ 79,937	(767,690)	427,623,151	(440,389,785)	792,233	(12,662,155)	9,703,288		(2,958,866)
Balance (in shares) at Apr. 30, 2020		79,936,996
Balance at Jan. 31, 2020		$ 69,127	(767,690)	420,206,242	(434,763,323)	775,191	(14,480,453)	14,429,920		(50,533)
Balance (in shares) at Jan. 31, 2020		69,129,001
Stock compensation expense				393,414			393,414			393,414
Shares issued for services		$ 110		49,890			50,000			50,000
Shares issued for services (in shares)		109,803
Reduction of derivative liabilities				765,424			765,424			765,424
Purchase of shares in subsidiary		$ 5,950		4,586,327			4,592,277	(4,592,277)
Purchase of shares in subsidiary (in shares)		5,950,000
Shares issued as debt issuance cost		$ 35		9,205			9,240			9,240
Shares issued as debt issuance cost (in shares)		35,000
Conversion of debt to equity		$ 4,715		1,580,437			1,585,152			1,585,152
Conversion of debt to equity (in shares)		4,713,192
Currency translation adjustment						17,042	17,042			17,042
Settlement of subsidiary's liability with stock				32,212			32,212			32,212
Net Income (Loss)					(5,626,462)		(5,626,462)	(134,355)		(5,760,817)
Balance at Apr. 30, 2020		$ 79,937	$ (767,690)	$ 427,623,151	$ (440,389,785)	$ 792,233	$ (12,662,155)	$ 9,703,288		$ (2,958,866)
Balance (in shares) at Apr. 30, 2020		79,936,996